News for MEI Pharma, Inc. (0JW9.L)

MEI Pharma, Inc. (Nasdaq: MEIP) (the ”œCompany”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the

MEI Pharma stock hits 52-week low at $2.72 amid market challenges

MEI Pharma reviews strategic options amid fiscal changes

Loading... Loading... Shares of CrowdStrike Holdings, Inc. CRWD fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock fr...

MEI Pharma halts capital return to focus on drug development

– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of...

– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital,...

MEI Pharma, Inc. , a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David...

In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds.

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -13.70% and 100%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

In this piece, we will take a look at the 11 cheapest stocks with the biggest upside.

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Infinity To Contact Him Directly To Discuss Their Op...

The marginal zone lymphoma pipeline possesses potential drugs in mid-stage developments to be launched in the near future. The total marginal zone lymphoma...

File New Definitive Consent Materials to Remove Entire MEI Pharma Board for Cause and Add Advisory Proposal Requesting the Return of Capital to...

Anson Funds Management LP (Trades, Portfolio), a prominent investment firm, recently added 864,188 shares of MEI Pharma Inc (MEIP) to its portfolio. This articl

On September 21, 2023, Anson Funds Management LP (Trades, Portfolio), a Dallas-based investment firm, added 816,128 shares of MEI Pharma Inc (MEIP) to its portf

The DLBCL market has a diverse pipeline, with the emergence of novel classes such as bi-specific antibodies, cancer vaccines, and allogeneic CAR-Ts in the...

NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...